AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10523001 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0
Study 10523001 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH treatment (0.15 IU/kg x day) for 1 week
Number of subjects: 0
Study 10523001 — intervention group
Group type: EXPERIMENTAL
Intervention: GH withdrawal
Number of subjects: 0
Study 8619701 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (600 mg in divided doses 12 hours before operation)
Number of subjects: 20
Study 8619701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1743354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine pretreatment
Number of subjects: 50
Study 1743354 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 50
Study 7041955 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 358
Study 7041955 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 358
Study 31753674 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV4
Number of subjects: 130
Study 31753674 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV3
Number of subjects: 130
Study 31264494 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring with a rapid fecal calprotectin test and symptom questionnaire every second month and in cases with increasing symptoms.
Number of subjects: 180
Study 31264494 — intervention group
Group type: COMPARATOR
Intervention: Control group filled in symptom questionnaire at baseline, 6 months, and 12 months, and for outpatient clinic appointments.
Number of subjects: 180
Study 26988800 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored intervention (Kanker Nazorg Wijzer)
Number of subjects: 462
Study 26988800 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 462
Study 26031572 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collection of high-risk human papillomavirus (HR-HPV) testing
Number of subjects: 500
Study 26031572 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 500
Study 23865647 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 200
Study 23865647 — intervention group
Group type: COMPARATOR
Intervention: Financial literacy control intervention
Number of subjects: 200
Study 21572316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique (group US)
Number of subjects: 120
Study 21572316 — intervention group
Group type: COMPARATOR
Intervention: Conventional surface landmark‐guided technique (group LM)
Number of subjects: 120
Study 18521599 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 138
Study 18521599 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 138
Study 16829774 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for women
Number of subjects: 0
Study 16829774 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for smokers with psychiatric diagnoses
Number of subjects: 0
Study 16829774 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for smokers addicted to illicit drugs, alcohol, or both
Number of subjects: 0
Study 16829774 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for African Americans
Number of subjects: 0
Study 16829774 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation interventions for older adults
Number of subjects: 0
Study 16829774 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation interventions for gay, lesbian, bisexual, and transgender smokers
Number of subjects: 0
Study 16829774 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation interventions for American Indians and Alaska Natives
Number of subjects: 0
Study 16829774 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation interventions for Hispanics
Number of subjects: 0
Study 16829774 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation interventions for Asian Americans
Number of subjects: 0
Study 15210658 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal enteral feeding (MEF)
Number of subjects: 42
Study 15210658 — intervention group
Group type: COMPARATOR
Intervention: No enteral feeding (NEF)
Number of subjects: 42
Study 11308434 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract (900 mg/d for 4 weeks, increased to 1200 mg/d if no adequate response)
Number of subjects: 200
Study 11308434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 11308434 — intervention group
Group type: EXPERIMENTAL
Intervention: St John's wort extract
Number of subjects: 200
Study 11308434 — intervention group
Group type: COMPARATOR
Intervention: St John's wort extract and Placebo
Number of subjects: 200
Study 9257200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg i.v. for dose 1, placebo for dose 2, ketorolac 30 mg i.v. for doses 3, 4, and 5 (Group 2)
Number of subjects: 248
Study 9257200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg i.v. for dose 1, ketorolac 30 mg i.v. for doses 3, 4, and 5 (Group 1)
Number of subjects: 248
Study 9257200 — intervention group
Group type: COMPARATOR
Intervention: Placebo for all doses (Group 3)
Number of subjects: 248
Study 8305166 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nitrendipine once daily for 12 weeks
Number of subjects: 20
Study 8305166 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg cilazapril once daily for 12 weeks
Number of subjects: 20
Study 8305166 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 20
Study 3324616 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 36
Study 3324616 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia (CA)
Number of subjects: 36
Study 28681263 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (n = 143)
Number of subjects: 195
Study 28681263 — intervention group
Group type: COMPARATOR
Intervention: Normal weight control group
Number of subjects: 195
Study 26950708 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 42
Study 26950708 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Number of subjects: 42
Study 25329848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity rubberized line
Number of subjects: 60
Study 25329848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity ethylene-vinyl acetate
Number of subjects: 60
Study 25329848 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity chicken leg skin
Number of subjects: 60
Study 25329848 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity pig foot skin
Number of subjects: 60
Study 25329848 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (didactic materials)
Number of subjects: 60
Study 22459388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 units of oral vitamin D3)
Number of subjects: 75
Study 22459388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22459388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 75
Study 19912184 — intervention group
Group type: EXPERIMENTAL
Intervention: UM-trained (50 interns)
Number of subjects: 100
Study 19912184 — intervention group
Group type: COMPARATOR
Intervention: Control (50 interns)
Number of subjects: 100
Study 19912184 — intervention group
Group type: COMPARATOR
Intervention: UMCG trainees
Number of subjects: 100
Study 18713490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing containing hyaluronic acid (HC + HA)
Number of subjects: 125
Study 18713490 — intervention group
Group type: COMPARATOR
Intervention: Reference hydrocolloid dressing not containing hyaluronic acid (HC)
Number of subjects: 125
Study 16629920 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training
Number of subjects: 99
Study 16629920 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional techniques)
Number of subjects: 99
Study 16629920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study 16629920 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 99
Study 12747455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastic chewing gum
Number of subjects: 20
Study 12747455 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 20
Study 11321442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbrokinase
Number of subjects: 51
Study 11321442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 8997575 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxitrol (neomycin sulphate 3500 IU/mL, polymyxin‐B sulphate 6000 IU/mL with dexamethasone 0.1%)
Number of subjects: 111
Study 8997575 — intervention group
Group type: COMPARATOR
Intervention: Maxidex (dexamethasone 0.1% alone)
Number of subjects: 111
Study 1617932 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily
Number of subjects: 250
Study 1617932 — intervention group
Group type: COMPARATOR
Intervention: cefaclor 250 mg three times daily
Number of subjects: 250
Study 6391390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120
Study 6391390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29252096 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 24
Study 30354632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed rotational atherectomy (RA)
Number of subjects: 200
Study 30354632 — intervention group
Group type: COMPARATOR
Intervention: Modified balloons (MB)
Number of subjects: 200
Study 26486011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 20 mg twice daily (n=96)
Number of subjects: 210
Study 26486011 — intervention group
Group type: COMPARATOR
Intervention: Micronized progesterone 400 mg twice daily (n=114)
Number of subjects: 210
Study 25174150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (Group 1)
Number of subjects: 120
Study 25174150 — intervention group
Group type: COMPARATOR
Intervention: Delayed Intervention Group (Group 2)
Number of subjects: 120
Study 25174150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 120
Study 21479565 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealants (60 sealants applied)
Number of subjects: 52
Study 21479565 — intervention group
Group type: COMPARATOR
Intervention: Composite restorations (12 restorations applied)
Number of subjects: 52
Study 21479565 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment of sealed lesions
Number of subjects: 52
Study 20647337 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/d selenium p.o. (as selenized yeast)
Number of subjects: 140
Study 20647337 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg/d selenium p.o. (as selenized yeast)
Number of subjects: 140
Study 20647337 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg selenium in men with highest quartile of baseline selenium
Number of subjects: 140
Study 20647337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 17468524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 166
Study 17468524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk in SGA babies
Number of subjects: 166
Study 17468524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk in AGA babies
Number of subjects: 166
Study 17468524 — intervention group
Group type: COMPARATOR
Intervention: Exclusive human milk (control)
Number of subjects: 166
Study 17468524 — intervention group
Group type: COMPARATOR
Intervention: Exclusive human milk in SGA babies (control)
Number of subjects: 166
Study 17468524 — intervention group
Group type: COMPARATOR
Intervention: Exclusive human milk in AGA babies (control)
Number of subjects: 166
Study 15259296 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CRO) 10 mg, administered twice in the first 24 hours postoperatively
Number of subjects: 35
Study 15259296 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tramadol/metamizol (TM) 100 mg tramadol + 1 g metamizol every 4 h for 24 h, placebo tablet at recovery
Number of subjects: 35
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion absorption profiling (AUC)
Number of subjects: 21
Study 12099518 — intervention group
Group type: COMPARATOR
Intervention: Conventional trough-level drug monitoring (C0)
Number of subjects: 21
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by AUC[0-12]
Number of subjects: 21
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by AUC[0-4]
Number of subjects: 21
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine exposure measured by C2 level
Number of subjects: 21
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 values above approximately 1500 microg/L by day 3 post-transplant
Number of subjects: 21
Study 12099518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough (C0) levels
Number of subjects: 21
Study 10233191 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s.)
Number of subjects: 116
Study 10233191 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM (pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s.)
Number of subjects: 116
Study 10233191 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC (pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d.)
Number of subjects: 116
Study 7570719 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 1011
Study 7570719 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 1011
Study 2112516 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 24
Study 2112516 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (0.8 mg)
Number of subjects: 24
Study 623044 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids alone (1 g/kg per day)
Number of subjects: 10
Study 623044 — intervention group
Group type: COMPARATOR
Intervention: Amino acids plus 100 g glucose daily
Number of subjects: 10
Study 29849514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 149
Study 29849514 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 149
Study 26428452 — intervention group
Group type: COMPARATOR
Intervention: standard CDC Tdap VIS (sVIS)
Number of subjects: 279
Study 26428452 — intervention group
Group type: COMPARATOR
Intervention: modified version Tdap VIS (mVIS)
Number of subjects: 279
Study 26428452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine information statement (VIS)
Number of subjects: 279
Study 26428452 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination intention (T2)
Number of subjects: 279
Study 24026037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 182
Study 24026037 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 182
Study 24026037 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 182
Study 24026037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and Carvedilol
Number of subjects: 182
Study 23273339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 10000
Study 23273339 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10000
Study 20709992 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg tablet once daily)
Number of subjects: 10739
Study 20709992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 19040336 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg, three times daily for 6 months (O group)
Number of subjects: 86
Study 19040336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day for 6 months (E group)
Number of subjects: 86
Study 19040336 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg and Ezetimibe 10 mg/day for 6 months (OE group)
Number of subjects: 86
Study 19040336 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 15867169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 20
Study 15867169 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg/d
Number of subjects: 20
Study 15867169 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and irbesartan
Number of subjects: 20
Study 15867169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11436193 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD‐GI meal (rolled oats, moderate GI, approximately 61)
Number of subjects: 6
Study 11436193 — intervention group
Group type: EXPERIMENTAL
Intervention: HI‐GI meal (puffed rice, high GI, approximately 82)
Number of subjects: 6
Study 11436193 — intervention group
Group type: COMPARATOR
Intervention: Control (water alone)
Number of subjects: 6
Study 9493502 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at 3 mg/kg bodyweight
Number of subjects: 0
Study 9493502 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine at 1 mg/kg bodyweight
Number of subjects: 0
Study 9493502 — intervention group
Group type: COMPARATOR
Intervention: Time of day (TOD)
Number of subjects: 0
Study 7995662 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent myocardial ischemia detected via 24-hour ambulatory ECG monitoring
Number of subjects: 42
Study 7995662 — intervention group
Group type: COMPARATOR
Intervention: No silent myocardial ischemia
Number of subjects: 42
Study 7995662 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent myocardial ischemia test
Number of subjects: 42
Study 3281386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol (0.1/0.2%) plus urea (17%)
Number of subjects: 20
Study 3281386 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone (0.25%)
Number of subjects: 20
Study 1734683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsically labeled bread (45Ca injected into wheat plants)
Number of subjects: 11
Study 1734683 — intervention group
Group type: COMPARATOR
Intervention: Extrinsically labeled bread (45Ca added to flour)
Number of subjects: 11
Study 28619 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg/day)
Number of subjects: 60
Study 28619 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate (6 g/day)
Number of subjects: 60
Study 30667557 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% sodium alginate (SA)
Number of subjects: 130
Study 30667557 — intervention group
Group type: COMPARATOR
Intervention: 0.4% sodium hyaluronate (SH) (control)
Number of subjects: 130
Study 28618737 — intervention group
Group type: EXPERIMENTAL
Intervention: Artcure Diffusional Patch
Number of subjects: 79
Study 28618737 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal diffusional patch
Number of subjects: 79
Study 25863956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovsynch plus 3000 IU hCG
Number of subjects: 80
Study 25863956 — intervention group
Group type: COMPARATOR
Intervention: Ovsynch (control)
Number of subjects: 80
Study 23584572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in airway pressure
Number of subjects: 50
Study 23584572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in airway flow
Number of subjects: 50
Study 23584572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaps in tidal volume
Number of subjects: 50
Study 23584572 — intervention group
Group type: EXPERIMENTAL
Intervention: Disappearance gaps in tidal volume, airway pressure, and flow waveforms
Number of subjects: 50
Study 21736531 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation
Number of subjects: 64
Study 21736531 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy
Number of subjects: 64
Study 19589242 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (6 months treatment)
Number of subjects: 76
Study 19589242 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy alone (control group)
Number of subjects: 76
Study 18023644 — intervention group
Group type: EXPERIMENTAL
Intervention: FPCIs
Number of subjects: 247
Study 18023644 — intervention group
Group type: COMPARATOR
Intervention: Toys
Number of subjects: 247
Study 15134184 — intervention group
Group type: EXPERIMENTAL
Intervention: unboosted amprenavir (APV)
Number of subjects: 84
Study 15134184 — intervention group
Group type: EXPERIMENTAL
Intervention: P459Ins (insertions in p6 protein)
Number of subjects: 84
Study 15134184 — intervention group
Group type: COMPARATOR
Intervention: wild-type (no insertions in p6 protein)
Number of subjects: 84
Study 11784832 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed cognitive assessment and treatment programme
Number of subjects: 240
Study 11784832 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed cognitive assessment
Number of subjects: 240
Study 11784832 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 240
Study 9701525 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 11
Study 9701525 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive (control)
Number of subjects: 11
Study 9701525 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive (uncontrolled trials)
Number of subjects: 11
Study 9701525 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative (uncontrolled trials)
Number of subjects: 11
Study 9701525 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication regimens based on omeprazole plus antibiotics and bismuth plus antibiotics
Number of subjects: 11
Study 8063983 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0